GlaxoSmithKline Pays $3BILLION for Marketing a Dangerous Diabetes Drug, Kick-Backs to Doctors and Manipulation of Medical Research
On November 3, the New York Times reported that GlaxoSmithKline (GSK) has settled another round of litigation against them to the tune of $3 BILLION. (The previous record was held by Pfizer, which in 2009 paid a fine of $2.3 billion for illegal marketing.) The charges against GSK included illegal marketing of the dangerous diabetes drug Avandia, kick-backs to doctors, and manipulation of medical research.

